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ABSTRACT
Objectives: There is a scarcity of literature reporting
hospital costs for treating out of hospital cardiac arrest
(OOHCA) survivors, especially within the UK. This is
essential for assessment of cost-effectiveness of
interventions necessary to allow just allocation of
resources within the National Health Service. We set
out primarily to calculate costs stratified against
hospital survival and neurological outcomes.
Secondarily, we estimated cost effectiveness based on
estimates of survival and utility from previous studies
to calculate costs per quality adjusted life year (QALY).
Setting: We performed a single centre (London)
retrospective review of in-hospital costs of patients
admitted to the intensive care unit (ICU) following
return of spontaneous circulation (ROSC) after OOHCA
over 18 months from January 2011 (following
widespread introduction of targeted temperature
management and primary percutaneous intervention).
Participants: Of 69 successive patients admitted over
an 18-month period, survival and cerebral performance
category (CPC) outcomes were obtained from review of
databases and clinical notes. The Trust finance
department supplied ICU and hospital costs using the
Payment by Results UK system.
Results: Of those patients with ROSC admitted to
ICU, survival to hospital discharge (any CPC) was 33/
69 (48%) with 26/33 survivors in CPC 1–2 at hospital
discharge. Cost per survivor to hospital discharge
(including total cost of survivors and non-survivors)
was £50 000, cost per CPC 1–2 survivor was £65 000.
Cost and length of stay of CPC 1–2 patients was
considerably lower than CPC 3–4 patients. The
majority of the costs (69%) related to intensive care.
Estimated cost per CPC 1–2 survivor per QALY was
£16 000.
Conclusions: The costs of in-hospital patient care for
ICU admissions following ROSC after OOHCA are
considerable but within a reasonable threshold when
assessed from a QALY perspective.
BACKGROUND
Out of hospital cardiac arrest (OOHCA)
causes 60 000 deaths in the UK and 300 000
deaths in the USA each year.1–3 Only 7–10% of
patients who suffer an OOHCA in the devel-
oped world will survive to hospital discharge
and obvious cognitive impairment will occur
in 10% of these survivors.1–3 Studies have
demonstrated improved high-quality survival
(Cerebral Performance Category (CPC) 1–2)
using targeted temperature management
(TTM) and primary percutaneous interven-
tion (PPCI);4–9 guidelines now incorporate
these interventions.10 In these selected trial
populations approximately 50% of patients
with return of spontaneous circulation
(ROSC) admitted to intensive care unit (ICU)
are discharged from hospital with a good
neurological outcome.4–7 This compares to
20–30% prior to the introduction of TTM and
universal PPCI.9 11
Outcome analysis of interventions used in
cardiac arrest management has a number of
unique challenges. The overall outcomes are
frequently poor—as represented by death or
survival with poor neurological outcome and
disability. Furthermore, it is often impossible to
determine prognosis for several days after
admission to hospital as patients are kept
sedated for temperature management. Primary
coronary interventions and prolonged periods
Strengths and limitations of this study
▪ First study looking at outcome related costs in
this population.
▪ Single centre study though population in study
representative of typical patients presenting to
any Heart Attack Centre in the UK.
▪ Tariff based re-imbursement system used to elimin-
ate interhospital variability in accounting methods.
▪ Methodology unique to UK tariff-based system
though all cost analyses susceptible to country
of origin healthcare funding system bias.
▪ Figures quoted current and applicable to current
commissioning and therefore of interest to wider
readership.
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of intensive care (with associated investigations) are deliv-
ered before any assessment of neurological damage or
prognosis is possible. The inevitable consequence of this is
that expensive treatment is delivered to people whose
outcome remains uncertain. There is accordingly much
interest in identifying robust early predictors of poor prog-
nosis following OOHCA.12 13 In order to make a useful
assessment of cost-effectiveness, the unit hospital costs of
treatment leading to the discharge of a high-quality
survivor must include costs associated with unsuccessful
treatment, that is, death or severe disability in others.
Interventions delivered early in the patient pathway may
clearly have a major impact on accumulated costs—espe-
cially if there is a possibility of delaying inevitable death in
the intensive in-hospital phase.
Literature review reveals a scarcity of published data
regarding economic costs of OOHCA, particularly
within the UK.14–18 The primary purpose of this study
was to provide an up-to-date UK estimate of the
in-hospital cost per high-quality OOHCA survivor, based
on CPC scoring, within a tertiary referral centre follow-
ing the introduction of PPCI and TTM in accordance
with guidelines.10 Secondarily, using follow-up outcome
data from similar studies, an exploratory estimation was
made to determine likely cost-effectiveness based on cost
per QALY gained.
METHODS
This study was a service evaluation under current
National Research Ethics Service deﬁnitions and used
retrospective data collected for clinical and administra-
tive purposes.19
Data collection
We performed a single centre retrospective review of
all patients admitted to our ICU following successful
resuscitation from OOHCA over an 18-month period
starting 1 January 2011. In keeping with prevailing guide-
lines, patients were assessed for PPCI suitability and tar-
geted temperature management was initiated unless
contraindicated.
A good outcome was deﬁned by a Pittsburgh Cerebral
Performance Category (CPC) Score of 1–2 (independence,
mild impairment). A poor outcome was deﬁned as death
or CPC 3–4 (moderate to severe impairment, coma).20
CPC score breakdown is shown in table 1.
Patients were identiﬁed from London Ambulance
Service (LAS) records and from a speciﬁc coding par-
ameter on the ICU electronic patient administration
database (AcuBase Critical IV, AcuBase Ltd, UK). LAS
records also provided details of the cardiac arrest.
Demographic data, diagnostic data, cardiac interven-
tions, organ support data, outcome and length of stay
data were extracted from paper and electronic patient
records. Electronic radiology databases (Centricity, GE
Systems) supplied data on diagnostic radiological inter-
ventions. Data were entered onto a new database for
analysis (Excel, Microsoft). CPC scoring was determined
from routine clinical, physiotherapy and occupational
therapy assessments recorded in the clinical notes for
each patient. These were assessed by two of the authors.
Where disagreement occurred, the best score was
accepted. In practice, this rarely occurred and did not
occur between CPC 2 and 3.
Cost analysis
‘Costs’ were deﬁned as the sum of money apportioned
to episodes of care as generated using the UK payment
by results (PbR) system, as outlined in ﬁgure 1.21 These
costs were provided at an individual patient level by the
Trust Finance Department.
After discharge, clinical coders translate clinical
records into diagnostic and procedure codes using
the ‘International Statistical Classiﬁcation of Diseases
and Related Health Problems’ (ICD-10) and the ‘Ofﬁce
for Population Census and Surveys Classiﬁcation of
Interventions and Procedures’ (OPCS-4) systems, respect-
ively.22 These codes are submitted to the Secondary Users
Service (SUS); the SUS is a nationally determined com-
puterised algorithm which generates a Health Resource
Group (HRG) descriptor based on the submitted codes.
Health Resource Groups typically reﬂect diagnoses and
interventions that commonly occur together. Each HRG
corresponds to a nationally set tariff, which is adjusted
annually. Such adjustments are derived from benchmark-
ing data submitted by National Health Service (NHS)
Trusts across the UK. There is currently no HRG for
Table 1 Cerebral Performance Category Scale20
Clinical findings
CPC 1 Good cerebral performance: conscious, alert, able to work, might have mild neurological or psychological deficit
CPC 2 Moderate cerebral disability: conscious, sufficient cerebral function for independent activities of daily life. Able to
work in sheltered environment
CPC 3 Severe cerebral disability: conscious, dependent on others for daily support because of impaired brain function.
Ranges from ambulatory state to severe dementia or paralysis
CPC 4 Coma or vegetative state: any degree of coma without the presence of all brain death criteria. Unawareness, even if
appears awake (vegetative state) without interaction with environment; may have spontaneous eye opening and
sleep/awake cycles. Cerebral unresponsiveness
CPC 5 Brain death: apnoea, areflexia, EEG silence, etc
CPC, Cerebral Performance Category.
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OOHCA. HRGs commonly assigned to these patients
include those associated with PPCI, or implantable cardi-
overter deﬁbrillator (ICD) implantation (see table 2 eg,
HRG codes and online supplementary appendix for
worked patient examples). Each HRG tariff is adjusted
according to whether the in-patient stay was elective or
non-elective and will include a standard set number of
days for inpatient care up to a point known as the ‘trim-
point’. Days in excess of this trimpoint are charged on a
daily rate. Since costs vary according to geography (eg,
inner city vs rural), a local Market Forces Factor (MFF) is
included as a multiplier. In our Trust an MFF of 1.2417 is
applied to reﬂect higher local costs.
Some aspects of inpatient care are not included within
the HRG—Critical Care is such an example. The adult
Critical Care Minimum Dataset (CCMDS) is a subset of
data relating to the patient’s Critical Care stay that gen-
erates a separate Critical Care HRG. The Critical Care
HRG is based on the peak number of organs supported
at any time during that Critical Care episode; PbR tariffs
at our trust for 2011–2012 are shown in table 3. Each
admission to Critical Care will generate a separate
Critical Care HRG that would be expected to reﬂect:
A. Hotel services
B. Nursing and other clinical staff
C. Therapies
D. Medical staff
E. Ward consumables
F. Drugs
G. Blood and blood products
H. Diagnostics undertaken while the patient is in critical
care, for example, pathology, plain ﬁlm X-rays, MRIs
Figure 1 Payment by Results System Cost Calculation.21
Table 2 Examples of coronary intervention PbR tariffs for year 2011–2012
Currency
code HRG Description
National average unit cost
2011/201223
Non-elective long stay
trimpoint (days)
Per day long stay
payment
EA36A Angiography only, no
intervention
£3221 20 £205
EA31Z POBA, BMS or DES 1–2 £4062 10 £205
EA49Z POBA, BMS or DES >2 £4915 12 £205
EA12Z Dual Chamber AICD £7248 34 £205
EA07Z Bivent AICD CRT-D £12 925 37 £205
AICD, automatic implantable cardioverter defibrillator; BMS, bare metal stent; CRT-D, cardiac resynchronisation therapy—defibrillator; DES,
drug eluting stent; HRG, Health Resource Group; PbR, payment by results; POBA, plain old balloon angioplasty.
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I. Medical and surgical equipment (include the costs
of specialist equipment, eg, CPAP and NIPPY
machines, and ensure that the costs of devices
excluded from the national tariff are also reported in
the reconciliation statement workbook).23
Certain medical devices and expensive treatments,
including ICDs are also charged separately to the HRG.
In our Trust the cost of each unit is calculated as an
average of all such devices implanted over the previous
year, thus eliminating the complexities of charging for
individual devices according to manufacturer; the
average ICD cost was £18 285 per unit in 2011–2012.
Data analysis
Data were assessed for normality using the d’Agostino-
Pearson omnibus test; all cost and length-of-stay data were
non-parametric and are presented as median (IQR)
values, rounded to the nearest £1000 and whole day,
respectively. Non-parametric data were analysed using a
Mann-Whitney U test. Correlation was assessed using a
Pearson’s R Correlation test. Data were analysed and pre-
sented using Microsoft Excel and Prism (V.5, GraphPad
Software, San Diego, California, USA).
Quality adjusted life years extrapolation
As a secondary analysis we extrapolated cost per quality
adjusted life years (QALY) for our data. QALYs are calcu-
lated by multiplying the number of additional years
gained by the ‘utility’ (an assessment of the quality of
those years).24 In the absence of long-term follow-up
data for our 2011–2012 patient population we extrapo-
lated QALY data using survival and utility from previous
follow-up studies. Historically studies have been consist-
ent in their reported long-term mean survival post-
OOHCA (6.13 years (Norwegian 1971–1992 data)14 and
6.2 years (Scottish 1991–1998 data)15). Studies have also
reported consistent utility following survival after
OOHCA, 0.72 in a 2004 American study,25 0.7 in a
Dutch study26 and 0.77 in a recent German study.16 In
order to avoid underestimating cost/QALY we used con-
servative estimates extrapolated from these studies of
6 years mean survival and 0.7 utility.
RESULTS
The ﬂow of OOHCA patients through our hospital in
the 18-month period from 1 January 2011 is shown in
ﬁgure 2. One hundred and ﬁfty-seven patients presented
directly to our hospital following OOHCA. Of these
patients, 56 required ICU admission. One hundred and
one patients were not admitted to ICU; of these, 37 sur-
vived to hospital discharge, having required ward care
only and 64 either died soon after admission to hospital
or were deemed to have such a poor prognosis that crit-
ical care was not indicated. None of these 101 patients
were included in this study.
On account of our position as a regional referral centre
for cardiac intervention, 13 additional patients were
transferred from other hospitals thus making at total of
69 patients admitted to our ICU following successful
resuscitation from OOHCA in the 18 months. During
this time period our ICU admitted 666 patients; OOHCA
patients thus represented 10% of all ICU admissions.
Baseline characteristics, cardiac interventions, causes of
cardiac arrest and critical care support of the 69 patients
is summarised in table 4. Over the course of their admis-
sion, these patients underwent a total of 598 chest radio-
graphs, 87 CT scans (all sites but mostly brain) and 9
MRI scans (brain and cardiac). Six patients had an auto-
matic ICD (AICD) inserted prior to discharge.
Outcomes
The outcomes of the 69 ICU patients are shown in
table 5. Of 69 ICU patients, 26 survived to hospital dis-
charge with a CPC 1–2; 7 survived to hospital discharge
with a CPC 3–4; the overall hospital survival rate was
47.8%. All patients discharged from ICU with a CPC 1–2
survived to hospital discharge and returned to their own
homes (2 via inpatient rehabilitation). Two returned
overseas and were lost to follow-up. Five of the 26
patients (19%) are known to have died in the ﬁrst year
after discharge.
Although 15 patients in total left ICU with a CPC 3–4,
eight died in hospital and thus only seven patients left
hospital alive. None had improved their CPC score by
hospital discharge and none returned directly to their
own homes. Four patients went to long-term rehabilita-
tion institutes, two to hospices and one was repatriated
Table 3 Imperial College Healthcare NHS Trust ICU PbR tariffs for year 2011–2012 shown against NHS reference costs for
that year
Currency code Critical care minimum data set (CCMDS)
National average unit
cost 2011/201223
Imperial college healthcare
NHS trust tariff 2011/2012
XC01Z Adult Critical Care, 6 or more organs supported £1796 £1819
XC02Z Adult Critical Care, 5 organs supported £1745 £1819
XC03Z Adult Critical Care, 4 organs supported £1586 £1717
XC04Z Adult Critical Care, 3 organs supported £1401 £1554
XC05Z Adult Critical Care, 2 organs supported £1223 £1318
XC06Z Adult Critical Care, 1 organ supported £868 £969
XC07Z Adult Critical Care, 0 organs supported £631 £295
NHS, National Health Service.
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to a hospital outside our region. Four of these patients
died within the year and thus 3 of 15 remained alive at
1 year.
Cost analysis
Total costs
The total ICU cost for the 68 UK patients (1 overseas
patient was excluded) was £1 166 000. The total number
of ICU days was 696. Thus cost per ICU day was £1700
(£1 166 000/696). The total hospital cost of the 68 UK
patients was £1 699 000, with total number of hospital
days of 1653 and cost per undifferentiated hospital day
£1000 (£1 698 000/1653). The total non-ICU costs were
£533 000, with total number of non-ICU days 957 and
the cost per non-ICU hospital day £557 (£533 000/957).
Intensive care costs represented 69% of the total costs
and for each patient was a mean of 66% of their individ-
ual cost.
Cost analysis and outcome
Costs and length of stay are shown stratiﬁes by outcome
in tables 6 and 7. The average (median) cost of a
CPC 1–2 patient hospital (ICU+non-ICU) stay was
signiﬁcantly (p<0.005) lower at £29 000 than that of a
Figure 2 Presentation of OOHCA patients to our regional centre. Flow of patients presenting with OOHCA to our hospital.
A total of 157 patients were brought by ambulance to our institution. Fifty-six of these were admitted to intensive care unit (ICU)
and 101 were not admitted to ICU. A further 13 patients were admitted to our ICU following OOHCA presenting to another
hospital (total 69 patients). Of the ICU patients 33 survived to hospital discharge, 28 died (21 on ICU, 7 on the ward
subsequently). Of the 101 OOHCA not admitted to ICU at our institution 37 were discharged from hospital alive, 64 died. Of
these 44 died in A&E, 6 died in the theatre/recovery area (prior to transfer to definitive ICU bed), 4 died in the catheter laboratory
and 10 died on the wards.
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CPC 3–4 patient (£53 000) as shown in ﬁgure 3. The
length of stay was signiﬁcantly longer in CPC 3–4
patients (p<0.005). There was also a signiﬁcant correl-
ation between length of stay and cost with much longer
length of stay in ICU and hospital for the CPC 3–4
patients (0.9795 (p<0.0001) and 0.6193 (p<0.0001)
respectively; see ﬁgure 4). While the average overall hos-
pital cost per patient admitted to ICU was £20 000 (this
includes non-survivors), the overall hospital cost per sur-
vivor of any CPC was £51 000 (£1 698 000/33). The total
hospital cost per high-quality survivor (deﬁned as
CPC 1–2) was £65 000 (£1 698 000/26). Thus a major
determinant of cost for the CPC 1–2 group was the
burden of cost of the non-survivors and CPC 3–4 patient
group. Taking into account the deaths of ﬁve patients in
the year following hospital discharge the cost per CPC
1–2 1-year survivor was £81 000 (£1 698 000/21).
QALY analysis
QALY data were extrapolated using survival and utility
from previous studies (see Methods). Using a conserva-
tive estimate for survival following OOHCA of 6 years,
the life year cost per high-quality survivor is estimated to
be £11 000 (£65 000/6) and using a conservative utility
estimate of 0.7, cost per QALY of a high-quality survivor
is £16 000 (£11 000/0.7).
DISCUSSION
To our knowledge this is the ﬁrst UK study using individ-
ual case costing to assess the economic burden of
OOHCA in patients requiring intensive care. This may
be reﬂective of the speciﬁc challenges of completing
such a cost analysis within the UK. A fully ‘bottom-up’
approach summing individual pathology, radiology, staff-
ing, drugs, cardiology and hotel services costs per
patient is extremely challenging as these ﬁgures are
embedded within the HRG costing. We have used the
best of the data available to us—re-imbursements calcu-
lated by the hospital ﬁnance department based on
tariffs per ICU day and the tariff cost of a typical HRG
which in turn are based on costs collected from hospitals
across the National Health Service. Sixty-nine per cent
of our costs were ICU costs calculated on an individual
patient basis as the product of ICU days and maximum
organ support. We expect these to be an accurate repre-
sentation of the true cost. Thirty-one per cent of our
costs were outside of ICU costs and a combination of
the cost of individual interventions such as ICD implant-
ation and the HRG tariff. While the interventions are
accurate on an individual basis, the HRG costs are more
of an ‘average’ reﬂection of the type of admission.
Good quality survival (hospital discharge with CPC
1–2) occurred in 26/69 (38%) patients with an overall
survival to hospital discharge of 33/69 (48%). This is a
Table 4 Patient characteristics, causes, cardiac and ICU
interventions
Patient characteristics
Age 63.5±14.7
Male sex 50/69 (72%)
VF/VT as initial rhythm 50/69 (72%)
Bystander CPR 36/69 (52%)
Cardiac interventions
Angiography (<24 h from admission) 48/69 (70%)
Angiography (>24 h from admission) 4/69 (6%)
PCI at initial angiography 34/48 (71%)
Repeat interventions (2 or more) 6/69 (9%)
Therapeutic hypothermia 64/69 (93%)
IABP (Intra-aortic balloon pump) 21/69 (30%)
AICD (inserted before hospital discharge) 6/69 (9%)
Causes of cardiac arrest
Cardiac cause 54/69 (78%)
Respiratory arrest 5/69 (7%)
Pulmonary embolus 2/69 (3%)
Alcohol intoxication 2/69 (3%)
Epileptic seizure 1/69 (1%)
Electrolyte disturbance 1/69 (1%)
Cerebrovascular accident 1/69 (1%)
Unknown 3/69 (4%)
ICU Support
Ventilation 68/69 (99%)
Inotropes and pressors 60/69 (87%)
RRT 9/69 (13%)
Tracheostomy 15/69 (22%)
Tracheostomy at ICU discharge 4/41 (10%)
AICD, automatic implantable cardioverter defibrillator; CPR,
cardiopulmonary resuscitation; ICU, intensive care unit; PCI,
primary coronary intervention; RRT, renal replacement therapy;
VF/VT, ventricular fibrillation-ventricular tachycardia.
Table 5 ICU and hospital survival and discharge destination stratified by outcome
Survival (69 patients admitted) Hospital discharge destination
ICU discharge Hospital discharge
Own home Rehabilitation Repatriation Hospicen Per cent n Per cent
CPC 1 20 29.0 22* 31.9 18 1 3 0
CPC 2 6 8.7 4 5.8 3 1 0 0
CPC 3 6 8.7 5 7.2 0 3 1 1
CPC 4 9 13.0 2 2.9 0 1 0 1
Total 41 59.4 33 47.8 21 6 4 2
*Represents the addition of two patients whose CPC score improved from 2 to 1 between ICU and hospital discharge.
CPC, cerebral performance category; ICU, intensive care unit.
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signiﬁcant improvement from the UK average 28.6%
overall survival to hospital discharge rate of ICU admis-
sions with ROSC reported by Nolan in 2007;11 possibly
representing both advances in management of these
patients and the volume-outcome relationship. Targeted
temperature management occurred in all but ﬁve
patients and coronary angiography was performed in
48/69 (70%) of patients.
In contrast to other costing studies, our study provides
fairly current data from the time period of 2011–2012,
following the widespread introduction of TTM and
PPCI. Unfortunately methodological differences make
direct comparison with other costing studies challen-
ging. Additionally, there are time dependant inﬂationary
changes and variations in purchasing power between dif-
ferent regions. Nationally these are adjusted by MFF cor-
rections embedded within the tariff-based system.
Internationally however, comparisons are much more
difﬁcult. We used individual patient costing data from an
18-month period to provide our cost ﬁgures but have
included only inhospital costs and we were unable to
estimate prehospital or posthospital costs.
In a 2004 Norwegian study Naess et al14 used data
from OOHCA patient identiﬁed via Emergency Medical
System (EMS) registers in Oslo over a 20-year period
(1972–1992) to identify all patients admitted to ICU
with ROSC following OOHCA of presumed cardiac aeti-
ology. They estimated costs per survivor of €40 642
(£33 761) and costs per life year gained of €6632
(£5509). Their cost per survivor included the cost of the
non-survivors. It also included prehospital, inhospital
and posthospital rehabilitation and nursing home costs
but used average ambulance costs and the product of
individual length of stay and average 24 h coronary care,
ward costs and nursing home costs, respectively. In con-
trast to our study, their mean length of stay (survivors
and non-survivors) in coronary care (3.4 days) and the
general ward (mean 6.8 days) was very short. Their
patients spent an additional mean 11.2 days in rehabilita-
tion/nursing home care. This shorter mean stay may
reﬂect a reduced survival percentage (26% of those with
ROSC compared with 48% in our study) and different
management protocols at the time of the study. UK data
of ICU patients admitted with ROSC following OOHCA
over a 10-year period 1995–2005 had similar survival
(28.6%) to the Norwegian study, again preceding the
widespread introduction of TTM and PPCI.11
In a 2004 Dutch study van Alem et al15 used data from
OOHCA patients identiﬁed via EMS registers in
Amsterdam over 2 years (2000–2002) and calculated the
cost of a survivor to be €28 636 (£23 788) and a non-
survivor to be €2383 (£1979). They also included prehos-
pital, inhospital and posthospital care and used a more
‘bottom-up’ approach, however their cost per survivor
did not include the cost of the non-survivors. Their 50%
survival to hospital discharge of those with ROSC (72/
144 patients) was slightly higher than our overall survival
but their analysis included patients with rapid ROSC and
return of consciousness who might bypass ICU direct to
CCU in our study and were not included. Their lengths
of critical care stay were considerably shorter with mean
2.85 ICU days, 4.93 CCU days and 28.3 hospital days
total per survivor. Their much lower cost per non-
survivor (£1979 compared with £14 192) may be a reﬂec-
tion of a majority of non-survivors who did not even
survive to hospital or ICU admission.
Table 6 Costs (ICU and total) stratified by outcome
Cost in 1000s (GBP)
CPC 1–2 CPC 2–3 Deceased All Patients
ICU Total ICU Total ICU Total ICU Total
Total 540 858 257 344 368 497 1166 1699
Minimum 4 9 23 40 1 2 1 2
25th centile 7 16 30 43 4 8 5 9
Median 13 29 32 53 8 10 12 20
75th centile 24 38 48 53 16 22 22 36
Maximum 122 142 50 56 36 42 122 142
CPC, cerebral performance category; GBP, British Pound Sterling; ICU, intensive care unit.
Table 7 Length of stay (ICU and total) to nearest day, stratified by outcome
LOS in days
CPC 1–2 CPC 2–3 Deceased All Patients
ICU Total ICU Total ICU Total ICU Total
Total 324 736 154 647 218 270 696 1653
Minimum 3 5 15 42 1 1 1 1
25th centile 4 12 18 44 3 3 4 5
Median 8 18 19 57 6 6 7 12
75th centile 13 34 28 102 10 11 12 27
Maximum 73 103 29 259 21 24 73 259
CPC, cerebral performance category; ICU, intensive care unit; LOS, length of stay.
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In a 2008 German study Graf et al16 used 3-year data
from ICU admissions with ROSC following cardiac arrest
from a single hospital (1999–2001 inclusive). They com-
pleted an individually costed ‘bottom up’ approach,
including prehospital, posthospital and inhospital costs
to calculate their cost per survivor of €49 952 (£41 495),
cost per life year gained of €10 107 (£8396) and esti-
mated cost per QALY (5-year survivors only) of €13 126
(£10 904). Their study also included inhospital cardiac
arrests (accounting for 31% of patients). Nevertheless
their survival to hospital discharge was similar at 42%
(compared with 48% in our study). Their mean overall
(survivors and non-survivors) ICU stay was 9 days (com-
pared with 10.2), with a mean hospital stay of 25 days
(compared with 24.3). Mean daily ICU cost was €2693
(£2237) compared to £1675 and mean per patient ICU
costs were slightly lower at €17 832 (£14 813) compared
to £17 142. The results obtained via our method there-
fore correspond very well with the fully costed ‘bottom
up’ approach used by Graf et al.16
The major determinant of our calculated inhospital
cost was length of stay—in particular length of ICU stay.
Our length of hospital and ICU stay is higher than previ-
ously reported in UK studies (although comparable to
that reported by Graf et al).16 Nolan et al11 reported a
median ICU length of stay of 2.9 days in ICU survivors
of OOHCA (our median 10 days) with a median hospital
length of stay of 18 days in hospital survivors of OOHCA
(our median 27 days). However, survival to hospital dis-
charge was 28.6% compared with 48% in our study.
While the increased length of stay may reﬂect delays
introduced by TTM to clinical course and delays in prog-
nostication, it also may reﬂect improved survival in our
population. It is also possible that in our institution we
are relatively slow at arriving at a withdrawal of active-
care consensus with patients’ families. This may reﬂect
local experience and the nature, ethnic and religious
background of the population of North West London.
Variation in the practices of withdrawal both within the
UK and Europe is well recognised.27 It is notable that
Figure 3 Graph demonstrating
costs (median, 25th and 75th
centiles and minimum and
maximum values) both for ICU
(light grey) and total (ICU and
non-ICU) stay in hospital (dark
grey) for different outcome
groups.
Figure 4 Graph demonstrating
length of stay (median, 25th and
75th centiles and minimum and
maximum values) both for ICU
(light grey) and total (ICU and
non-ICU) stay in hospital (dark
grey) for different outcome
groups.
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the 2007 Nolan study median time to start withdrawal
was 2.4 days which by current standards is early to
attempt accurate prognostication especially in the era of
TTM.12
Of our patients admitted to ICU with ROSC following
OOHCA, the cost per survivor to hospital discharge was
£51 000, the cost per CPC 1–2 survivor was £65 000, and
the average cost per CPC 1–2 1-year survivor was £80 879.
The NHS is economically stretched by limited resources,
an increasingly ageing population and increasing avail-
ability of expensive drugs and treatments. Fairness (or
‘justice’) in resource allocation in such conditions
requires an understanding of the economic cost-beneﬁt
ratio of interventions. Studies have shown that survival
curves following cardiac arrest return to normal after 1–2
years28–31 and systematic review demonstrates that survi-
vors have a good quality of life.32 Treatments can be use-
fully assessed using QALYs. The threshold value for cost
effectiveness in the UK is £30 000.33 In our study the
extrapolated cost per QALY of a high-quality survivor is
£16 000, well within this threshold. This is using very con-
servative estimates for utility and survival and thus the
true cost per QALY is likely to be lower than this.
This study was a retrospective review of prospectively
collected data and had a number of limitations some of
which have already been discussed above. It is important
to highlight that our aim was to investigate the cost-
effectiveness of ICU admission with ROSC following
OOHCA and thus our population was patients admitted
to ICU rather than all-comers with ROSC. Some of the
best outcomes following OOHCA will be in patients not
captured in this study (ie, those with rapid ROSC, con-
sciousness and admission to CCU or normal ward level
care). These patients will be less expensive.
Although the costing method used is a nationally
imposed model, it is somewhat dependent on how indi-
vidual clinical coders enter data, thus some caution is
needed in applying our ﬁgures to other institutions.
Also, the approach that is adopted in determining prog-
nosis and managing end-of-life issues in our service may
not be representative of wider practice. However, we do
not feel that these issues undermine the general level of
costs estimated. In addition we made no attempt to esti-
mate prehospital or posthospital costs of patient care.
Other limitations of this study include the retrospective
nature of the study and the fact that CPC status was
decided by review of the clinical notes. Finally in the
absence of longer term follow-up data for our 2011–
2012 population, our QALY data was an extrapolation
using previously published values for survival and utility.
CONCLUSION
Patient survival to hospital discharge of 48% following
ICU admission with ROSC after OOHCA in our institu-
tion is considerably higher than historically reported in
UK studies, though comparable with recent clinical
trials. The major determinant of hospital cost is ICU
length of stay. The overall cost burden for high-quality
survivors is inﬂated by high costs of treating those who
die or survive with poor outcome and who necessarily
experience long lengths of stay. However, the majority of
patients discharged from hospital have a CPC of 1–2,
and treatment including ICU is thus cost-effective by
current standards with an estimated cost per QALY of
£16 000.
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